Solomon, Scott D.

Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities–Sleep Heart Health Study

Roca, G. Q., Redline, S., Claggett, B., Bello, N., Ballantyne, C. M., Solomon, S. D., & Shah, A. M. (2015) · Circulation

Obstructive Sleep Apnea ResearchSleep and related disorders

Cited by 182

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Jackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 175

Incidence and Predictors of Hyperkalemia in Patients With Heart Failure

Desai, A. S., Swedberg, K., McMurray, J. J. V., Granger, C. B., Yusuf, S., Young, J. B., Dunlap, M. E., Solomon, S. D., Hainer, J. W., Olofsson, B., et al. (2007) · Journal of the American College of Cardiology

Potassium and Related DisordersHeart Failure Treatment and Management

Cited by 170

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials

Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal

Lipoproteins and Cardiovascular HealthHeart Failure Treatment and Management

Cited by 160

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

Jackson, A. M., Jhund, P. S., Anand, I. S., Düngen, H.-D., Lam, C. S. P., Lefkowitz, M. P., Linssen, G., Lund, L. H., Maggioni, A. P., Pfeffer, M. A., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 156

Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction

Bello, N. A., Claggett, B., Desai, A. S., McMurray, J. J. V., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., & Solomon, S. D. (2014) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 147

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

Serenelli, M., Böhm, M., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., DeMets, D. L., et al. (2020) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 138

Comparison of time-to-first event and recurrent-event methods in randomized clinical trials

Claggett, B., Pocock, S., Wei, L. J., Pfeffer, M. A., McMurray, J. J. V., & Solomon, S. D. (2018) · Circulation

Statistical Methods in Clinical TrialsStatistical Methods and Bayesian Inference

Cited by 118

Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

Lewis, E. F., Kim, H.-Y., Claggett, B., Spertus, J., Heitner, J. F., Assmann, S. F., Kenwood, C. T., Solomon, S. D., Desai, A. S., Fang, J. C., et al. (2016) · Circulation: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 114

Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk

Seidelmann, S. B., Feofanova, E., Yu, B., Franceschini, N., Claggett, B., Kuokkanen, M., Puolijoki, H., Ebeling, T., Perola, M., Salomaa, V., et al. (2018) · Journal of the American College of Cardiology

Genetic Associations and EpidemiologyNutrition, Genetics, and Disease

Cited by 97

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 95

Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction

Kosiborod, M. N., Bhatt, A. S., Claggett, B. L., Vaduganathan, M., Kulac, I. J., Lam, C. S. P., Hernandez, A. F., Martinez, F. A., Inzucchi, S. E., Shah, S. J., et al. (2023) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 86

Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes

CHARM Investigators and Committees, Kristensen, S. L., Jhund, P. S., Lee, M. M. Y., Køber, L., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K., et al. (2017) · Cardiovascular Drugs and Therapy

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 83

Left Ventricular Ejection Time is an Independent Predictor of Incident Heart Failure in a Community-Based Cohort

Biering-Sørensen, T., Querejeta Roca, G., Hegde, S. M., Shah, A. M., Claggett, B., Mosley, T. H., Butler, K. R., & Solomon, S. D. (2018) · European Journal of Heart Failure

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 76

Prognosis and Response to Therapy of First Inpatient and Outpatient Heart Failure Event in a Heart Failure Clinical Trial: MADIT-CRT

Skali, H., Dwyer, E. M., Goldstein, R., Haigney, M., Krone, R., Kukin, M., Lichstein, E., McNitt, S., Moss, A. J., Pfeffer, M. A., et al. (2014) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiac pacing and defibrillation studies

Cited by 76

Worsening Renal Function and Outcome in Heart Failure Patients with Reduced and Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment: Data from the CHARM-Study Programme

Damman, K., Solomon, S. D., Pfeffer, M. A., Swedberg, K., Yusuf, S., Young, J. B., Rouleau, J. L., Granger, C. B., & McMurray, J. J. V. (2016) · European Journal of Heart Failure

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 75

The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling

Ruwald, A.-C., Kutyifa, V., Ruwald, M. H., Solomon, S., Daubert, J. P., Jons, C., Brenyo, A., McNitt, S., Do, D., Tanabe, K., et al. (2015) · European Heart Journal

Cardiac pacing and defibrillation studiesCardiac Arrest and Resuscitation

Cited by 74

Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials

McMurray, J. J. V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Maria Langkilde, A., Reicher, B., Senni, M., Shah, S. J., et al. (2024) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 60

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44

Widening racial differences in risks for coronary heart disease.

Nadruz, W., Claggett, B., Henglin, M., Shah, A. M., Skali, H., Rosamond, W. D., Folsom, A. R., Solomon, S. D., & Cheng, S. (2018) · Circulation

Health disparities and outcomesCardiovascular Health and Risk Factors

Cited by 43

Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction

Docherty, K. F., Shen, L., Castagno, D., Petrie, M. C., Abraham, W. T., Böhm, M., Desai, A. S., Dickstein, K., Køber, L. V., Packer, M., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 42

Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF

Yang, M., Henderson, A. D., Talebi, A., Atherton, J. J., Chiang, C.-E., Chopra, V., Comin-Colet, J., Kosiborod, M. N., Kerr Saraiva, J. F., Claggett, B. L., et al. (2025) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementHormonal Regulation and Hypertension

Cited by 41

Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF

Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 41

Natural Language Processing for Adjudication of Heart Failure in a Multicenter Clinical Trial: A Secondary Analysis of a Randomized Clinical Trial

Cunningham, J. W., Singh, P., Reeder, C., Claggett, B., Marti-Castellote, P. M., Lau, E. S., Khurshid, S., Batra, P., Lubitz, S. A., Maddah, M., et al. (2024) · JAMA Cardiology

Artificial Intelligence in HealthcareHeart Failure Treatment and Management

Cited by 38